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Mesenchymal stem cells (MSCs) are a promising tool for studying intractable diseases. Unfortunately, MSCs can easily undergo
cellular senescence during in vitro expansion by losing stemness. The aim of this study was to improve the stemness and
diﬀerentiation of MSCs by using glabridin, a natural ﬂavonoid. Assessments of cell viability, cell proliferation, β-galactosidase
activity, diﬀerentiation, and gene expression by reverse transcription PCR were subsequently performed in the absence or
presence of glabridin. Glabridin enhanced the self-renewal capacity of MSCs, as indicated by the upregulation of the OCT4 gene.
In addition, it resulted in an increase in the osteogenic diﬀerentiation potential by inducing the expression of osteogenesis-
related genes such as DLX5 and RUNX2. We conﬁrmed that glabridin improved the osteogenesis of MSCs with a signiﬁcant
elevation in the expression of OSTEOCALCIN and OSTEOPONTIN genes. Taken together, these results suggest that glabridin
enhances osteogenic diﬀerentiation of MSCs with induction of the OCT4 gene; thus, glabridin could be useful for stem
cell-based therapies.
1. Introduction
Mesenchymal stem cells (MSCs) derived from various tissues
are very promising sources for cellular therapies and regener-
ative medicine, since they are easily accessible and diﬀerenti-
ate into a variety of cell types, including osteoblasts,
chondrocytes, and adipocytes [1, 2]. MSCs have been applied
to cell-based therapies due to their numerous advantages
including anti-inﬂammatory and immunomodulatory eﬀects
[3, 4]. However, despite the high expansion potential of
MSCs, when cultured in vitro, they easily undergo prolifera-
tion arrest prior to signiﬁcant telomere shortening due to
intrinsic and/or extrinsic environmental factors [5, 6]. It is
known that oxidative stress—due to an imbalance between
the production of free radicals and the ability of the body to
detoxify their harmful eﬀects—is one of the main factors that
induce senescence [7]. Senescence represents an arrested
state in which cells remain viable but not stimulated to pro-
liferate by serum or passage in culture. Cellular senescence
of MSCs reduces functionality, which might impair their
regenerative potential [8]. Therefore, MSCs need to be
expanded for clinical application through in vitro long-term
cultivation without early growth stop or cellular senescence.
Glabridin is an isoﬂavan compound found in the root
extract of licorice [9]. A number of studies have reported that
glabridin exhibits protective functions against oxidative
stresses and cytotoxicity [10, 11]. In addition, it has been
reported to inhibit cancer stem cell-like properties of human
breast cancer cells, suggesting that it could enhance the eﬀec-
tiveness of breast cancer therapy [12]. Recently, it was also
shown that glabridin attenuates oxidative damage and cellu-
lar dysfunction and upregulates osteoblast diﬀerentiation
genes in osteoblastic cells [13]. These ﬁndings suggest the
interesting possibility that glabridin could have positive
eﬀects on MSC culture in vitro. Although there is some evi-
dence that glabridin protects cells from oxidative stress, no
study has investigated whether glabridin can prevent MSC
senescence. We therefore hypothesized that glabridin would
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preserve MSC functionality and would be beneﬁcial for MSC
culture in vitro.
The aim of this study was to examine the eﬀects of
glabridin on MSC in vitro culture. Treatment of MSCs with
glabridin provided a favorable environment that improved
stemness through upregulation of the OCT4 gene, which is
involved in pluripotency. To investigate the eﬀects of glabri-
din on the diﬀerentiation potential of MSCs, we examined
genes for osteogenic factors (DLX5 and RUNX2), chondro-
genic factors (BMP7 and SOX9), and adipogenic factors
(PPARG and C/EBPA). We found that the treatment of MSCs
with glabridin led to osteoblast diﬀerentiation with the
upregulation of osteoblast markers such as OSTEOCALCIN
and OSTEOPONTIN. To our knowledge, this is the ﬁrst
study to indicate that glabridin is a beneﬁcial factor that
induces the OCT4 gene and improves osteogenic
Table 1: Primer sequences used for RT-PCR.
Gene
Primer sequence
(5′–3′) Annealing temperature (
°C) Product size (bp)
GAPDH
Forward: GTGGTCTCCTCTGACTTCAACA
Reverse: CTCTTCCTCTTGTGCTCTTGCT
62 210
OCT4
Forward: GACAACAATGAGAACCTTCAGGAGA
Reverse: TTCTGGCGCCGGTTACAGAACCA
62 218
SOX2
Forward: AACCAAGACGCTCATGAAGAAG
Reverse: GCGAGTAGGACATGCTGTAGGT
62 341
cMYC
Forward: TCGGATTCTCTGCTCTCCTC
Reverse: CGCCTCTTGACATTCTCCTC
62 413
KLF4
Forward: ATTCTCTCCAATTCGCTGACCC
Reverse: TTCAGCACGAACTTGCCCAT
62 376
NANOG
Forward: ATAGCAATGGTGTGACGCAG
Reverse: GATTGTTCCAGGATTGGGTG
62 219
P53
Forward: TCGACATAGTGTGGTGGTGC
Reverse: TTGGACTTCAGGTGGCTGGA
58 480
LIN28
Forward: GCTCCGTGTCCAACCAGCAG
Reverse: TTTCCTTTTGGCCGCCTCTC
58 376
P16
Forward: CGAATAGTTACGGTCGGAGG
Reverse: GCATGGTTACTGCCTCTGGT
62 309
DLX5
Forward: ACCATCCGTCTCAGGAATCG
Reverse: ACCTTCTCTGTAATGCGGCC
60 384
RUNX2
Forward: TTGCAGCCATAAGAGGGTAG
Reverse: GTCACTTTCTTGGAGCAGGA
58 470
PPARG
Forward: TCTCTCCGTAATGGAAGACC
Reverse: GCATTATGAGACATCCCCAC
55 474
C/EBPA
Forward: CCAAGAAGTCGGTGGACAAGAA
Reverse: TCATTGTCACTGGTCAGCTCCA
62 145
BMP7
Forward: CCAACGTCATCCTGAAGAAATAC
Reverse: GCTTGTAGGATCTTGTTCATTGG
60 271
SOX9
Forward: GGTTGTTGGAGCTTTCCTCA
Reverse: TAGCCTCCCTCACTCCAAGA
61 400
P21
Forward: GCGATGGAACTTCGACTTTG
Reverse: CGTTTTCGACCCTGAGAGAGTC
60 285
OSTEOCALCIN
Forward: CGCAGCCACCGAGACACCAT
Reverse: GGGCAAGGGCAAGGGGAAGA
62 405
OSTEOPONTIN
Forward: GAGACCCTTCCAAGTAAGTCCA
Reverse: GATGTCCTCGTCTGTAGCATCA
62 354
COMP
Forward: GAAGAACGACGACCAAAAGGAC
Reverse: GTCACAAGCATCTCCCACAAAG
62 232
TYPE I COLLAGEN
Forward: CACAGAGGTTTCAGTGGTTTGG
Reverse: GCACCAGTAGCACCATCATTTC
62 191
AP2
Forward: AAGAAGTAGGAGTGGGCTTTGC
Reverse: CCACCACCAGTTTATCATCCTC
62 381
LPL
Forward: AGAGAGGACTTGGAGATGTGGA
Reverse: GGAAGACTTTGTAGGGCATCTG
62 264
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diﬀerentiation of MSCs during culture in vitro. These ﬁnd-
ings will be useful for preparing highly functional MSCs
for cell-based clinical applications.
2. Materials and Methods
2.1. Cell Culture. The bone marrow was collected from
healthy donors after obtaining written informed consent.
This study was approved by the Institutional Review Boards
of Severance Hospital of Yonsei University Health System,
Seoul, Korea. As previously described, mononuclear cells
were isolated by Ficoll-Hypaque density gradient centrifuga-
tion (Pharmacia Biotech, Uppsala, Sweden), and the MSCs
were cultured using the plastic adherence method [14].
The cells were maintained in DMEM Low Glucose supple-
mented with 10% fetal bovine serum (FBS) and 1% penicil-
lin/streptomycin (P/S) at 37°C with 5% CO2 (all from
Invitrogen, Carlsbad, CA, USA). The medium was changed
every 3 or 4 days. The cells were subcultured using 0.05%
trypsin/EDTA (Invitrogen) when they reached approxi-
mately 80–90% conﬂuence. Glabridin (0.01–100 μM) was
purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Cell Viability Test. The cells were seeded into 12-well
plates (Corning Inc., Corning, NY, USA) at a density of
4× 104 cells/well for assessment of cell viability. The next
day, cells were treated with glabridin (0.01–100 μM), directly
added to the medium, for 24h. The viability of the cells was
analyzed using a CCK-8 kit (Dojindo Co., Kumamoto,
Japan), which measures cell metabolic activity, according to
the manufacturer’s instructions [15]. Brieﬂy, 50 μM of the
CCK-8 solution was added to each well of the culture plate
at the end of the culture period. After 4 h of incubation,
absorbance was measured at 450 nm. Cells incubated without
glabridin were used as a control.
2.3. Cell Proliferation Assay. Cells were plated at a density
of 2× 104/well in 12-well plates (Corning) for analysis of
cell growth. When the cells were replated, glabridin
(0.01–100 μM) was added to each well of the culture plate.
A proliferation assay was performed using a CCK-8 kit.
CCK-8 contains WST-8 [2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-dissulfophenyl)-2H-tetrazolium,
monosodium salt], which produces a water-soluble formazan
dye upon reduction in the presence of an electron carrier.
CCK-8, being nonradioactive, allows sensitive colorimetric
assays for the determination of the number of viable cells
during cell proliferation. Cultures were maintained for 7 days
and then analyzed for cell growth on days 1, 4, and 7
according to the manufacturer’s instructions. Cells incu-
bated with the culture medium alone were used as a control.
The absorbance of the cells was normalized to their respec-
tive day 0 absorbance.
2.4. Reverse Transcription PCR (RT-PCR). Total RNA was
isolated using TRIzol reagent (Invitrogen). Standard reverse
transcription was performed using transcriptase II (Invitro-
gen). RT-PCR was performed using PCR primers (Bioneer,
Daejeon, Korea) under the conditions listed in Table 1.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
level was used as an internal control. The signal intensity
of the product was normalized to its respective GAPDH
signal intensity.
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Figure 1: (a) Eﬀect of glabridin on cell viability in bone marrow-derived mesenchymal stem cells (MSCs). Cell viability of MSCs treated with
an increasing concentration of glabridin was determined by a CCK-8 assay. The data are expressed as the mean± SD of three independent
experiments. ∗P < 0 05 versus untreated control. (b) Growth rates of cultured MSCs. Cells were cultivated with an increasing
concentration of glabridin for 7 days. Proliferation activity was measured using a CCK-8 kit containing WST-8. The data are expressed as
the mean± SD of three independent experiments.
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2.5. Colony Forming-Unit-Fibroblast (CFU-F) Assay. For
assessment of self-renewal properties, a CFU-F assay was
performed. Brieﬂy, 1× 103 cells were plated in 100mm
dishes (Corning), and the cells were cultured for 14 days.
Following incubation for 14 days, the cells were washed
with phosphate-buﬀered saline (PBS; Invitrogen). Then,
the cells were stained with 0.5% crystal violet (Sigma-
Aldrich) for 5min at room temperature, and stained colonies
were counted.
2.6. β-Galactosidase Staining. Senescent cells show an
increase in cell size and the senescence-associated expres-
sion of β-galactosidase activity. A senescence detection
kit (BioVision Inc., CA, USA) was used to histochemically
detect β-galactosidase activity in cultured cells, according
to the manufacturer’s instructions. Brieﬂy, cultured cells
were washed with PBS and ﬁxed with 4% paraformalde-
hyde at room temperature. After washing with PBS, cells
were incubated with β-galactosidase staining solution for
24 h at 37°C. The number of β-galactosidase-stained cells
was counted under a light microscope (Olympus-IX71;
Olympus, Tokyo, Japan).
2.7. Diﬀerentiation Assay. To induce MSC diﬀerentiation
into osteoblasts, chondrocytes, and adipocytes, cells were
cultured in osteogenic induction medium, chondrogenic
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Figure 2: Eﬀect of glabridin on stemness and senescence in MSCs. (a) Stemness marker expression in MSCs treated with an increasing
concentration of glabridin. (b) Stemness was evaluated by a CFU-F assay. The number of colonies (>50 cells) was counted. (c) P53, P16,
and P21 mRNA expression levels were analyzed using reverse transcription PCR (RT-PCR). (d) Senescence-associated (SA) β-gal assay.
The number of β-gal-positive cells was counted. The data are expressed as the mean± SD of three experiments. ∗P < 0 05 and ∗∗P < 0 01
versus untreated control.
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induction medium, or adipogenic induction medium for 3
weeks (Cambrex, Lonza, MD, USA), respectively. The
medium was changed every 3 or 4 days, and the cells for
chondrogenic diﬀerentiation were treated with 10 ng/ml
transforming growth factor (TGF)-β3 (Cambrex) whenever
the medium was replaced. The induced cells were stained
with von Kossa to conﬁrm osteogenesis, safranin O to con-
ﬁrm chondrogenesis, and oil red O to conﬁrm adipogenesis.
Images of the stained cells were taken using a phase micro-
scope (Olympus-IX-71). To measure the calcium content in
osteogenesis, the Calcium LiquiColor kit (Stanbio Labora-
tory, Boerne, USA) was used according to a previously
described method [16]. Brieﬂy, the cells were washed with
PBS and treated with 0.5N HCl. After shaking for 3 h by
using an orbital shaker, the supernatant was transferred to
a new tube for analysis. Ortho-cresolphthalein complexone
(OCPC) was added to the sample, and absorbance was deter-
mined at 550nm. For quantitative analysis of adipogenesis,
absorbance was measured at 500nm after destaining with
isopropanol for 30min according to a previously reported
method [16]. To quantitatively evaluate chondrogenesis,
the absorbance of sulfated glycosaminoglycan was mea-
sured at 656 nm by using the Blyscan assay kit (Biocolor
Ltd., County Antrim, UK). Brieﬂy, the supernatant was
transferred to a new tube and each sample was mixed with
1,9-dimethylmethylene blue (DMMB) dye, which is used
to measure sulfated glycosaminoglycan (sGAG) content,
according to the manufacturer’s instructions and a previ-
ous report [17].
2.8. Statistical Analysis.Quantitative data are expressed as the
means± standard deviation (SD). Statistical comparisons
were performed by a Student’s t-test and one-way analysis
of variance (ANOVA) with post hoc Bonferroni corrections.
The diﬀerences were considered statistically signiﬁcant at
P < 0 05. Statistical analyses were performed using SPSS
software (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Eﬀect of Glabridin on the Viability and Proliferation of
MSCs. To investigate the eﬀect of glabridin on MSC survival,
cells were cultured with increasing concentrations (0.01–
100 μM) of glabridin for 24 h and then cell viability was mea-
sured using a CCK-8 assay. Glabridin at concentrations of
0.01–50 μM had no eﬀect on cell survival, whereas incuba-
tion with 100 μM glabridin decreased the cell viability of
MSCs (Figure 1(a)). These results show that 100 μM glabri-
din itself was cytotoxic to MSCs.
To evaluate the eﬀect of glabridin on MSC proliferation,
MSCs were cultured for 7 days to determine whether glabri-
din stimulates MSC growth, and then cell proliferation was
determined using the CCK-8 assay. A decrease in cell growth
was detected in MSCs cultured with 100 μM glabridin, while
the cells cultured with 0.01–50 μM glabridin exhibited
proliferation properties similar to those of the control cells
(Figure 1(b)). These results show that glabridin did not
facilitate the growth rates of the MSCs.
3.2. Eﬀect of Glabridin on MSC Stemness. In order to identify
the self-renewal capacity of MSCs, we analyzed the expres-
sion levels of stemness markers in the MSCs cultured with
0.01–100 μM glabridin. NANOG, SOX2, cMYC, KLF4, and
LIN28 were similarly expressed with all concentrations of
glabridin (Figure 2(a)). Interestingly, the OCT4 gene—in-
volved in the self-renewal of undiﬀerentiated stem cells—was
markedly detected in MSCs cultured with 5 μM glabridin
(Figure 2(a)). Therefore, we chose this concentration of glab-
ridin (5 μM) for all subsequent cell experiments. The CFU-F
assay was used to investigate whether OCT4 expression with
glabridin promotes the self-renewal capacity of MSCs.
Glabridin signiﬁcantly enhanced the self-renewal capacity
of the treated cells compared with that of the control cells
(Figure 2(b)). In addition, to conﬁrm whether glabridin
aﬀected the cell cycle, the mRNA expression levels of P53,
P16INK4a, and P21Cip1 in MSCs treated with glabridin were
measured. The expression levels of P53, P16INK4a, and
P21Cip1 of MSCs treated with glabridin were decreased com-
pared to those in control cells (Figure 2(c)). We next exam-
ined whether glabridin prevented MSC senescence. MSCs
treated with glabridin showed a decrease in the percentage
of β-galactosidase-stained cells compared to control cells
although there was no signiﬁcance (Figure 2(d)). Together,
these results suggest that glabridin augments the self-
renewal capacity with upregulation of the OCT4 gene.
3.3. Changes of Diﬀerentiation Potential in MSCs by
Glabridin. We subsequently examined the osteogenesis-,
chondrogenesis-, and adipogenesis-related gene expression
levels in the MSCs after glabridin treatment. DLX5 and
RUNX2 genes, which are involved in osteogenesis, were
Re
la
tiv
e 
m
RN
A
 le
ve
l
0.0
DLX5 RUNX2 BMP7 SOX9 PPARG C/EBPA
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Control
Glabridin (5 휇M)
⁎
⁎
Figure 3: Gene expression in MSCs following glabridin treatment.
RT-PCR analysis of osteogenic, chondrogenic, and adipogenic
markers was performed in control and glabridin-treated MSCs.
Relative mRNA expression levels of trilineage-associated genes in
the control and glabridin-treated MSCs. Expression levels relative
to GAPDH are shown. The data are expressed as the mean± SD of
three experiments. ∗P < 0 05 versus untreated control.
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markedly upregulated by glabridin (Figure 3). With respect
to chondrogenesis, the BMP7 gene was upregulated, whereas
the expression of SOX9 gene was similar to MSCs treated
with glabridin (Figure 3). The adipogenesis-related C/EBPA
gene was similarly expressed in glabridin-treated MSCs
compared to that in control cells, while the expression level
of the PPARG gene decreased with glabridin treatment
(Figure 3). These results indicate that glabridin strongly
aﬀects the osteogenic potential of MSCs.
3.4. Glabridin Enhances Osteogenesis of MSCs. To evaluate
the diﬀerentiation capacity of MSCs, cells were induced
by glabridin to form osteoblasts, chondrocytes, and adipo-
cytes. MSCs treated with glabridin showed higher amounts
of von Kossa staining, which detects calcium-containing
mineralized nodules, compared to control cells (Figure 4(a)),
and the expression of OSTEOCALCIN and OSTEOPONTIN
genes of osteogenic diﬀerentiation markers was upregulated
in MSCs treated with glabridin (Figure 4(b)). Moreover, we
conﬁrmed that MSCs cultured with glabridin had a higher
degree of calcium accumulation compared to control cells
although there were no signiﬁcant diﬀerences (Figure 4(c)).
Chondrogenesis was assessed by safranin O staining. After
chondrogenic induction,MSCs culturedwith glabridin exhib-
ited a slightly higher chondrogenic diﬀerentiation capacity
(Figure 5(a)). However, the COMP and the TYPE I COLLA-
GEN genes of the chondrogenic diﬀerentiation markers were
similarly expressed despite chondrogenic induction in both
conditions (Figure 5(b)). Sulfated glycosaminoglycan con-
tent was slightly increased in MSCs grown with glabridin,
irrespective of the PCR data (Figure 5(c)). There were no sig-
niﬁcant diﬀerences. In adipogenesis, glabridin slightly
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Figure 4: Eﬀect of glabridin on osteogenesis in MSCs. (a) Osteogenic diﬀerentiation was evaluated by von Kossa staining (magniﬁcation:
200x). (b) Osteogenic potential was analyzed by OSTEOCALCIN and OSTEOPONTIN gene expression using RT-PCR. (c) Diﬀerentiation
of MSCs into osteoblasts was determined by calcium quantiﬁcation. The data are expressed as the mean± SD of three experiments.
∗P < 0 05 and ∗∗P < 0 01 versus untreated control.
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suppressed adipogenic diﬀerentiation as shown in
Figure 6(a). In addition, the AP2 and LPL genes of
adipogenesis-related markers were slightly decreased in
glabridin-treated cells without a signiﬁcant diﬀerence
(Figure 6(b)). We also conﬁrmed that the absorbance value
of lipid droplets was reduced in MSCs induced with glabridin
(Figure 6(c)). Together, these results imply that glabridin
prominently enhanced the osteogenic diﬀerentiation capacity
of MSCs by upregulating the OSTEOCALCIN and OSTEO-
PONTIN genes.
4. Discussion
Of the adult stem cells, MSCs have been widely used for
clinical applications because of their plastic and anti-
inﬂammatory eﬀects [18, 19]. Although MSCs represent a
new approach to treat intractable diseases, clinical trials using
these cells have been impeded by low quantities of cells and
diﬃculty of cell culture, described as cellular or replicative
senescence. MSCs can easily enter a state of growth arrest,
known as senescence, despite high self-renewal capacity by
internal and/or external stimuli [5]. Therefore, the culture
and maintenance of MSCs without the loss of stemness are
very critical for their extensive clinical use.
In general, cells are aﬀected by multiple biochemical and
biophysical factors such as the extracellular matrix (ECM)
and soluble factors [20, 21]. Previously, we prevented senes-
cence and augmented MSC growth using poly-L-lysine
(PLL) of ECM proteins [22]. PLL deﬁnitely improved the
proliferation capacity and functionality of MSCs. However,
using PLL as a coating substrate is time-consuming because
culture vessels should be incubated and dried for a long time
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Figure 5: Eﬀect of glabridin on chondrogenesis in MSCs. (a) Chondrogenic diﬀerentiation was evaluated by safranin O staining
(magniﬁcation: 200x). (b) Chondrogenic potential was analyzed by levels of COMP and TYPE I COLLAGEN gene expression using
RT-PCR. (c) Diﬀerentiation of MSCs into chondrocytes was determined by glycosaminoglycan quantiﬁcation. The data are expressed
as the mean± SD of three experiments.
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after PLL coating. Recently, Kim et al. reported that glabridin,
one of the major active ﬂavonoids in licorice, attenuates
oxidative damage and improves osteogenic diﬀerentiation
function [13]. It was also reported that glabridin inhibits
the cancer stem cell-like properties in hepatocellular carci-
noma cells [23]. Cellular senescence is very closely related
to oxidative stress [24]. In the present study, we applied glab-
ridin, which has an antioxidant activity, to a cell culture con-
dition. We found that glabridin did not signiﬁcantly aﬀect
the viability of bone marrow-derived MSCs. In addition,
glabridin did not activate cell proliferation in in vitro culture.
We analyzed the expression levels of OCT4, NANOG, SOX2,
cMYC, KLF4, and LIN28 genes known as stemness markers
of stem cells to investigate molecular patterns of self-
renewal capacity. NANOG, SOX2, cMYC, KLF4, and LIN28,
which are involved in pluripotency and self-renewal of stem
cells, were similarly expressed in all conditions. OCT4, an
essential transcription factor in the maintenance of pluripo-
tency, is expressed in embryonic stem cells [25]. In addition,
OCT4 is a very important gene for the generation of induced
pluripotent stem cells [26]. It is known that OCT4, as a spe-
ciﬁc marker of embryonic stem cells, is also expressed in
MSCs [27]. However, it is hard to detect the expression of
OCT4 in MSCs because it readily disappears during culture
in vitro [28]. Recently, Piccinato et al. showed that a high
OCT4 gene expression might be a potential hallmark and
predictor of greater in vitro lifespan and growth potential
of MSCs [29]. These results indicate that the expression
level of the OCT4 gene may be a speciﬁc factor that aﬀects
MSC senescence.
In this study, the OCT4 gene was strongly induced in the
presence of 5 μM glabridin. However, there was no dose-
dependent OCT4 expression by glabridin. Rather, MSCs
treated with 100 μM glabridin did not express OCT4. The
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Figure 6: Eﬀect of glabridin on adipogenesis in MSCs. (a) Adipogenic diﬀerentiation was evaluated by oil red O staining (magniﬁcation:
400x). (b) Adipogenic capacity was analyzed by AP2 and LPL mRNA expression using RT-PCR. (c) Absorbance was determined after oil
red O destaining for quantitative analysis. The data are expressed as the mean± SD of three experiments.
8 Stem Cells International
expression ofOCT4might be suppressed by a decrease in via-
bility as shown in Figure 1. When MSCs were treated with
glabridin, a signiﬁcant increase in their self-renewal capacity
was observed, implying that glabridin enhances CFU-F
capacity by inducing the OCT4 gene. Several studies have
reported that cellular senescence is regulated by the P53,
P16INK4a, and P21Cip1 pathways via the accumulation of reac-
tive oxygen species [30–32]. We have conﬁrmed that the P53,
P16INK4a, and P21Cip1 mRNA expression levels were inhib-
ited by glabridin although there was no signiﬁcance. These
results coincide with previous results, demonstrating that cel-
lular senescence of MSCs could be suppressed via inhibition
of P53 and P21Cip1 [33]. In addition, glabridin delayed MSC
senescence as observed by β-galactosidase staining, showing
that glabridin positively aﬀects cell senescence in MSCs cul-
tured in vitro. Together, these results strongly support that
glabridin has antisenescence eﬀects.
Recently, it was reported that MSC treatment with
glabridin resulted in a signiﬁcant elevation of alkaline phos-
phatase (ALP) activity, collagen content, and expression of
osteoblast diﬀerentiation genes [13]. To investigate the eﬀects
of glabridin on MSC diﬀerentiation potential, trilineage
(osteogenesis, chondrogenesis, adipogenesis)-related key
transcription factors were analyzed by RT-PCR after treat-
ment with glabridin as compared with control cells. When
MSCs were treated with glabridin, signiﬁcant increases in
the gene expression of DLX5 and RUNX2 for osteogenesis
were observed. In the diﬀerentiation assay, our results dem-
onstrated that glabridin could signiﬁcantly improve osteo-
genic diﬀerentiation capacity with signiﬁcant upregulation
of OSTEOCALCIN and OSTEOPONTIN genes of osteogen-
esis markers. Regarding chondrogenesis, sulfated glycosami-
noglycan contents were also elevated by glabridin, but
glabridin had no eﬀects on the chondrogenic diﬀerentiation
marker genes. Moreover, glabridin slightly attenuated adi-
pogenic diﬀerentiation capacity with changes in the expres-
sion levels of genes associated with adipogenesis. These
results correspond to a previous result, demonstrating that
overexpression of DLX5, a key factor for osteogenesis,
inhibited the expression of adipogenic marker genes [34].
In the present results, enhancement of osteogenesis inhib-
ited adipogenesis of human MSCs, due to the reverse rela-
tionship between osteogenic and adipogenic diﬀerentiation.
In summary, we have shown that glabridin improved
osteogenic diﬀerentiation capacity of MSCs by inducing the
expression of the OCT4 gene of the pluripotency factors
and augmenting DLX5 and RUNX2 gene expression for oste-
ogenesis as shown in Figure 7. We thus conclude that glabri-
din could be used in the MSC culture system in vitro.
Furthermore, MSC culture using glabridin will contribute
greatly to regenerative medicine and cell-based therapies
including bone diseases.
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